Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
<p><strong>Background:</strong> Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that have been proposed as treatments for patients admitted to hospital with COVID-19.</p> <br> <p><strong>Methods:</strong> In this randomised, cont...
Main Authors: | RECOVERY Collaborative Group, Horby, PW, Staplin, N, Peto, L, Emberson, JR, Campbell, M, Pessoa-Amorim, G, Basnyat, B, Thwaites, L, Van Doorn, R, Hamers, RL, Nel, J, Amuasi, J, Stewart, R, Ghosh, D, Hamilton, F, Desai, P, Easom, N, Majumdar, J, Hine, P, Chadwick, D, Cooke, G, Sharp, S, Esmail, H, Baillie, JK, Buch, MH, Faust, SN, Jaki, T, Jeffery, K, Juszczak, E, Knight, M, Lim, WS, Montgomery, A, Mukherjee, A, Mumford, A, Rowan, K, Thwaites, G, Mafham, M, Haynes, R, Landray, MJ |
---|---|
Format: | Internet publication |
Language: | English |
Published: |
2024
|
Similar Items
-
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
by: Schilling, WHK, et al.
Published: (2023) -
Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore
by: Soh, Alexius Matthias Sheng En, et al.
Published: (2024) -
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group
Published: (2020) -
Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial
by: Png, ME, et al.
Published: (2024) -
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
by: Butler, CC, et al.
Published: (2022)